Case Report
Copyright ©The Author(s) 2020.
World J Gastroenterol. Apr 28, 2020; 26(16): 1979-1986
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1979
Table 1 Patient characteristics
CharacteristicsData (n = 6)
Gender
Male3 (50)
Female3 (50)
Age (yr)70 (47-81)
Tumor stage IV16 (100)
Localization1
Right2 (33.3)
Sigmoid2 (33.3)
Rectal1 (16.7)
Mucinous appendix1 (16.7)
KRAS status1
Mutated6 (100)
Normal0 (0)
Table 2 Normalized CXCL5 gene expression levels and progression-free survival after bevacizumab-containing treatment onset in the six cases reported in this study
Case number123456
PFS after BVZ-containing treatment onset (mo)181212363
Overall PFS after BVZ-containing treatment onset (mo)12 (12-18)3 (3-6)
Normalized CXCL5 gene expression10.7003.6550.00223.43020.39032.900
Overall normalized CXCL5 gene expression3.655 (0.002-10.700)23.430 (20.390-32.900)